Trastuzumab Deruxtecan in Advanced Breast Cancer
Recruiting · NCT07180264 · Observational (researchers observe without assigning treatment) · Lead sponsor: Wenjin Yin
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged ≥18 and older
- Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
- ECOG 0-1
Exclusion criteria
- During pregnancy and lactation
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiaotong University - Shanghai, China